SCHEMBL4764759

SCHEMBL4764759

CC(=O)OCc1ccc(N(c2ccccc2)c2ccc(C=O)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ALDH3A1 P30838 1/20 0.42
ALDH1A3 P47895 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.41
IDH1 O75874 1/20 0.40
CA12 O43570 1/20 0.40
AKR1B10 O60218 1/20 0.40
AKR1B1 P15121 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159711 0.90 ALDH1A1 (0.70) ALDH1A1MAPTHPGDIDH1LMNA
SCHEMBL14063388 0.90 ALDH1A1 (0.70) ALDH1A1MAPTHPGDIDH1LMNA
SCHEMBL3082528 0.85 ALDH1A1 (0.60) ALDH1A1MAPTHPGDIDH1CA12
SCHEMBL14063396 0.84 ALDH1A1 (0.51) ALDH1A1MAPTHPGDCTDSP1LMNA
E1501 SCHEMBL11503249 0.84 ALDH1A1 (0.76) ALDH1A1IDH1CA12AKR1B10AKR1B1
SCHEMBL14063390 0.83 ALDH1A1 (0.62) ALDH1A1MAPTHPGDIDH1LMNA
SCHEMBL14063402 0.83 ALDH1A1 (0.53) ALDH1A1MAPTHPGDCTDSP1LMNA
SCHEMBL9581057 0.82 ALDH1A1 (0.64) ALDH1A1MAPTHPGDLMNATSHR
SCHEMBL14063398 0.82 ALDH1A1 (0.64) ALDH1A1MAPTHPGDLMNATSHR
SCHEMBL14063393 0.82 ALDH1A1 (0.64) ALDH1A1MAPTHPGDLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1424942-B1 PORPHYRINS WITH ENHANCED MULTI-PHOTON ABSORPTION CROSS-SECTIONS FOR PHOTODYNAMIC THERAPY UNIV MONTANA STATE (US) 2008-12-31 EP disclosed
EP-1424942-A4 PORPHYRINS WITH ENHANCED MULTI-PHOTON ABSORPTION CROSS-SECTIONS FOR PHOTODYNAMIC THERAPY UNIV MONTANA STATE (US) 2005-11-23 EP disclosed
US-6953570-B2 Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy MONTANA STATE UNIVERSITY (US) 2005-10-11 US disclosed
EP-1424942-A1 PORPHYRINS WITH ENHANCED MULTI-PHOTON ABSORPTION CROSS-SECTIONS FOR PHOTODYNAMIC THERAPY Montana State University-Bozeman (US) 2004-06-09 EP disclosed
US-20030105070-A1 Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy NICKEL JOINT TRUST, THE 2003-06-05 US disclosed
WO-2003017846-A1 PORPHYRINS WITH ENHANCED MULTI-PHOTON ABSORPTION CROSS-SECTIONS FOR PHOTODYNAMIC THERAPY MONTANA STATE UNIVERSITY-BOZEMAN (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105070-A1 Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy HMBS, PPOX, PAICS ALDH1A1 2239/4885MAPT 1431/4885HPGD 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.